Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...
Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results